Skip to content
Tenfell
Closed tender
Published 29 Jun 2021

KCL-00001335 - CANTOP

King's College London · London

Key facts

Estimated value
£1,000,000
Closing date
22 Jul 2021
Contract starts
01 Sep 2021
Contract ends
02 Sep 2024
Procedure
Open procedure (above threshold)
Buyer type
Education

Description

CANTOP-RCT is a non-commercial, UK multi-centre, pragmatic, parallel group, randomised, double-blind, placebo-controlled clinical trial of cannabidiol (CBD) as a treatment in early psychosis.

The primary objective of this trial is to test whether treatment with CBD improves psychotic symptoms when added to Treatment as Usual (TAU) in Clinical High Risk (CHR) patients.

Patients will be randomised in a 1:1 ratio to either TAU + Cannabidiol or TAU + Placebo. The sample size is 300 patients (n=150 per arm).

Patient recruitment will take place over 3 years. The total duration from first patient visit, to last patient visit, is anticipated to be 42 months.

The trial is co-sponsored by King's College London and South London & Maudsley NHS Foundation Trust and is funded by the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme.

Service providers are invited to tender for the manufacture of the investigational medicinal products (including procurement of GMP grade CBD), complete associated stability and QC validation/testing, QP release, and store and distribute the IMP to UK trial sites.

In order to compliantly participate in the tender process, all bidders are expected to fulfill the scope and specification requirements.

Additional information: Is a Recurrent Procurement Type? : No

Categories (CPV)

Similar open tenders

About King's College London

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.